The Movement Disorder Journal and News

Parkinson's, Aging, and the Gut Microbiome

57 min · 4 de jun de 2026
Portada del episodio Parkinson's, Aging, and the Gut Microbiome

Descripción

Researchers are now more than ever convinced that Parkinson's disease could start in the digestive tract years before symptoms could ever develop. In this episode, Dr. Julie Anderson and Dr. Minna Schmitt of the Buck Institute for Research and Aging explore the growing body of research connecting the gut, the brain, and Parkinson's disease, including the role of the microbiome, inflammation, and the gut-brain axis. We discuss what scientists are discovering, what it could mean for earlier diagnosis, and why gut health has become one of the most talked-about areas of Parkinson's research today.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Movement Disorder Journal and News!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

6 episodios

episode Neuralight's Eye-Movement Software and the MDS-UPDRS artwork

Neuralight's Eye-Movement Software and the MDS-UPDRS

In this episode, we sit down with Dr. Eitan Raveh, VP of Clinical Partnerships at NeuraLight, to explore a technology that could reshape how Parkinson's disease is measured and tracked in clinical trials. For nearly four decades, the MDS-UPDRS has been the gold standard for evaluating Parkinson's progression, but a new study suggests that a simple eye-tracking test, administered on a tablet in about ten minutes, may be more sensitive at detecting disease progression than the scale neurologists have relied on for generations. Dr. Raveh walks us through NeuraLight's landmark longitudinal study, what the Amplitude of Saccadic Hypometria actually measures, and why two of the scientists who helped build the MDS-UPDRS are now co-authors on a paper showing it may have met its match. If you follow Parkinson's research, drug development, or the future of digital biomarkers in neurology, this is a conversation you won't want to miss.

18 de jun de 202632 min